Sanofi plans to accelerate expansion in Ukraine

8 May 2015

French pharma major Sanofi (Euronext: SAN) plans to accelerate its expansion in Ukraine over the next several years, despite the current economic crisis in the country and the loss of Crimea and Donbass, according to Jean-Paul Scheuer, general director of Sanofi Ukraine.

According to Mr Scheuer, Donbass and the Crimea accounted for about 20% of the company’s sales in Ukraine. In addition, the combined share of both regions in the Ukrainian pharmaceutical market is estimated at 20%. Despite the crisis in Ukraine, Sanofi sales in the country in 2014 increased by 3% compared to 2013, while its market share reached 3.7%.

Move to cheaper drugs as a result of crisis

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK